دورية أكاديمية
Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: A pilot project
العنوان: | Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: A pilot project |
---|---|
المؤلفون: | Cristina Mitric, Brian How, Emad Matanes, Zainab Amajoud, Hiba Zaaroura, Hai-Hac Nguyen, Angela Tatar, Shannon Salvador, Walter H. Gotlieb, Susie Lau |
المصدر: | Gynecologic Oncology Reports, Vol 37, Iss , Pp 100842- (2021) |
بيانات النشر: | Elsevier, 2021. |
سنة النشر: | 2021 |
المجموعة: | LCC:Gynecology and obstetrics LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | Gynecology oncology, Chemotherapy, Alopecia, Scalp cooling, Gynecology and obstetrics, RG1-991, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Objective: Determine the efficacy of scalp cooling for the prevention of chemotherapy-induced alopecia in gynecology oncology patients. Methods: This prospective pilot study included patients diagnosed with a gynecological malignancy that received DigniCap™ scalp cooling. Patients were divided into two groups based on chemotherapy regimen: Carboplatin with area under the curve (AUC) 5–6 every three weeks and (1) conventional Paclitaxel 175 mg/m2 every three weeks or (2) Paclitaxel 80 mg/m2 weekly. A 1–10 visual analogue scale (1 no hair loss, 10 – complete hair loss) was used to assess degree of hair loss by patients themselves and by a certified dermatologist using photographs. Changes in quality of life and body image were measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire version 3 (EORTC QLQ-C30) and the Body Image Scale (BIS) for cancer patients. Results: Hair preservation occurred with use of a scalp cooling device for patients receiving weekly Paclitaxel (n = 20), but not conventional every three weeks Paclitaxel (n = 8). Ten of 15 patients (66.7%) in the dose-dense group lost less than 50% of their hair based on self-assessment and 14 of 16 (87.5%) based on dermatologist assessment. No patient in this group acquired a cranial prosthesis (wig). There was no difference between groups in terms of quality of life (QoL) and BIS scores. Conclusion: Scalp cooling may allow for hair preservation in gynecology oncology patients receiving Carboplatin AUC 5–6 and weekly Paclitaxel 80 mg/m2 combination chemotherapy. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2352-5789 |
Relation: | http://www.sciencedirect.com/science/article/pii/S2352578921001466; https://doaj.org/toc/2352-5789 |
DOI: | 10.1016/j.gore.2021.100842 |
URL الوصول: | https://doaj.org/article/c1fb103d4e3648a7be82a076e627bfeb |
رقم الأكسشن: | edsdoj.1fb103d4e3648a7be82a076e627bfeb |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 23525789 |
---|---|
DOI: | 10.1016/j.gore.2021.100842 |